Pharmacotherapy for nocturia in the elderly patient

Drugs and Aging

Volumn 24, Issue 4, 2007, Pages 325-343

  Asplund, Ragnar ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BACLOFEN; BUMETANIDE; DARIFENACIN; DESMOPRESSIN; DIURETIC AGENT; DOXAZOSIN; DUTASTERIDE; ESTRIOL SUCCINATE; ESTROGEN; FINASTERIDE; FUROSEMIDE; MELATONIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TOLTERODINE; TROSPIUM CHLORIDE; VASOPRESSIN;

BLADDER CAPACITY; BLADDER EMPTYING; BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELIRIUM; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; DRY EYE; DRY THROAT; ESTROGEN THERAPY; FALLING; FLUID INTAKE; FLUID RETENTION; GERIATRIC PATIENT; HALLUCINATION; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; LEG EDEMA; LOW DRUG DOSE; MEMORY DISORDER; META ANALYSIS; MICTURITION; MUCOSAL DISEASE; NAUSEA; NOCTURIA; OPTIMAL DRUG DOSE; POLYURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SLEEP; SLEEP DISORDER; SYSTEMATIC REVIEW; TACHYCARDIA; THIRST; THORAX PAIN; UNSPECIFIED SIDE EFFECT; URINE VOLUME; VERTIGO; VOMITING; XEROSTOMIA;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; ANTIDIURETIC AGENTS; DEAMINO ARGININE VASOPRESSIN; DIURETICS; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; NOCTURIA; PREVALENCE; SLEEP DISORDERS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 34247280425     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724040-00005     Document Type: Review

References (91)

1. Schulman CC, Asplund R, Desgrandchamps F, et al. The impact of nocturia on health status and quality of life in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol 2005; Suppl. 4 (2): 1-8
2. Asplund R. Nocturia: consequences for sleep and daytime activities and associated risks. Eur Urol 2005; Suppl. 3 (6): 24-32
3. Schatzl G, Temml C, Schmidbauer J, et al. Cross-sectional study of nocturia in both sexes: analysis of a voluntary health screening project. Urology 2000; 56: 71-5
4. Asplund R. Nocturia in the elderly in relation to thirst, dry antidimouth and dry eyes. Can J Urol 2004; 11 (4): 2322-6
5. van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisain tion Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 179-83
6. Abrams P. Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol 2005; Suppl. 3: 8-16
7. Chasens ER, Umlauf MG. Nocturia: a problem that disrupts sleep and predicts obstructive sleep apnea. Geriatr Nurs 2003; 24: 76-81
8. van Dijk L, Kooij DG, Schellevis FG. Nocturia in the Dutch adult population. BJU Int 2002; 90: 644-8
9. Weiss JP, Blaivas JG. Nocturia. Curr Urol Rep 2003; 4: 362-6
10. Asplund R, Åberg H. Diurnal rhythm of antidiuretic hormone in elderly subjects with nocturia. Med Sci Res 1991; 19: 765-6
11. Asplund R, Åberg H. Micturition habits of older people. Scand J Urol Nephrol 1992; 26: 345-9
12. Asplund R. Micturition habits and diuresis in relation to sleep and well-being in elderly subjects with emphasis on antidiuretic hormone [thesis]. Stockholm: Karolinska Institute, 1992
13. Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999; 84 (3): 297-301
14. Asplund R, Åberg H. Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 1992; 10: 98-104
15. Asplund R. Nocturnal giddiness in relation to nocturia and other symptoms and to medication in the elderly. Arch Gerontol Geriatr 2005; 40: 103-11
16. van Balen R, Steyerberg EW, Polder JJ, et al. Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthop 2001; 390: 232-43
17. Donahue JL, Lowenthal DT. Nocturnal polyuria in the elderly person. Am J Med Sci 1997; 314: 232-8
18. Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992; 40: 1217-20
19. Nevalainen TH, Hiltunen LA, Jalovaara P. Functional ability after hip fracture among patients home-dwelling at the time of fracture. Cent Eur J Public Health 2004; 12: 211-6
20. Asplund R. Hip fractures, nocturia and nocturnal polyuria in the elderly. Arch Gerontol Geriatr 2006; 43: 319-26
21. Dew MA, Hoch CC, Buysse DJ, et al. Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom Med 2003; 65: 63-73
22. Benz RL, Pressman MR, Hovick ET, et al. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000; 35: 1052-60
23. Asplund R. Sleep, health and visual impairment in the elderly. Arch Gerontol Geriatr 2000; 30: 7-15
24. Asplund R. Visual impairment, sleep and nocturia in the elderly. Arch Gerontol Geriatr 2005; 4: 61-7
25. Asplund R, Åberg HE. Oral dryness, nocturia and the menopause. Maturitas 2005; 50 (2): 86-90
26. Robertson GL, Norgaard JP. Vasopressin regulation of urine volume. BJU Int 2002; 90 Suppl. 3: 7-10
27. Asplund R. The nocturnal polyuria syndrome (NPS). Gen Pharm 1995; 26: 1203-9
28. Asplund R, Åberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Int Med 1991; 229: 131-4
29. Ozawa T, Oyanagi K, Tanaka H, et al. Suprachiasmatic nucleus Standardisain a patient with multiple system atrophy with abnormal circadian rhythm of arginine-vasopressin secretion into plasma. J Neurol Sci 1998, 21
30. Ouslander JG, Nasr SZ, Miller M, et al. Arginine vasopressin obstruclevels in nursing home residents with nighttime urinary incontinence. J Am Geriatr Soc 1998; 46: 1274-9
31. Asplund R. Nocturia in relation to sleep, somatic diseases and medical treatment in the elderly. BJU Int 2003; 91: 302-3
32. Reynard JM, Cannon A, Yang Q, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998; 81: 215-8
33. Pedersen PA, Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol 1988; 62: 14-7
34. Asplund R, Åberg H. Desmopressin in elderly women with increased nocturnal diuresis: a short-term study. Br J Urol 1993; 72: 42-5
35. Asplund R, Åberg H. Desmopressin in elderly subjects with antidiuretincreased nocturnal diuresis: a two-months study. Scand J Urol Nephrol 1993; 27: 77-82
36. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn 2004; 23: 302-5
37. Cvetkovic RS, Plosker GL. Desmopressin: in adults with nocturia. Drugs 2005; 65: 99-109
38. Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004; 60: 397-402
39. Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 1998; 48: 235-41
40. Mattiasson A, Abrams P, van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89: 855-62
41. Asplund R, Sundberg B, Bengtsson P. Desmopressin for the treatment of nocturnal polyuria in elderly subjects: a dose pharmacokinettitration study. Br J Urol 1998; 82: 642-6
42. Kuo HC. Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. Urology 2002; 59: 485-9
43. Moon du G, Jin MH, Lee JG, et al. Antidiuretic hormone in treatelderly male patients with severe nocturia: a circadian study. BJU Int 2004; 94: 571-5
44. Rembratt A, Norgaard JP, Andersson KE. Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003; 91: 642-6
45. Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003; 189: 1106-13
46. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004; 172: 1021-5
47. Craggs MD. Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation. BJU Int 2005; 96 Suppl. 1: 29-36
48. Congregado Ruiz B, Pena Outeirino XM, Campoy Martinez P, et al. Peripheral afferent nerve stimulation for treatment of lower urinary tract irritative symptoms. Eur Urol 2004; 45: 65-9
49. Andersson KE. Treatment of the overactive bladder syndrome and detrusor overactivity with antimuscarinic drugs. Contiics nence 2005; 1: 1-8
50. Kay G, Pollack BG, Romanzi LJ. Unmasking anticholinergic load: when 1 + 1 = 3. CNS Spectr 2004; Suppl. 15: 1-11
51. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-85
52. Kerbusch T, Wahlby U, Milligan PA, et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003; 56: 639-52
53. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-8
54. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 2005 Apr; 173 (4): 1214-8
55. Kachur JF, Peterson JS, Carter JP, et al. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J Pharmacol Exp Ther 1988; 247: 867-72
56. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22: 859-69
57. Waldeck K, Larsson B, Andersson KE. Comparison of ox-ybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997; 157: 1093-7
58. Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin: for overactive bladder. Drugs Aging 2003; 20: 857-64
59. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515-20
60. Beermann B, Hellstrom K, Rosen A. On the metabolism of propantheline in man. Clin Pharmacol Ther 1972; 13: 212-20
61. Thuroff JW, Chartier-Kastler E, Corcus J, et al. Medical treatelderly ment and medical side effects in urinary incontinence in the elderly. World J Urol 1998; Suppl. 1: 48-61
62. Madersbacher H, Murtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001; 19: 324-35
63. Haustein KO, Huller G. On the pharmacokinetics and metabo-placebolism of propiverine in man. Eur J Drug Metab Pharmacokinet 1988; 13: 81-90
64. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients: a double-blind, placebo-controlled clinical study. Eur Urol 2000 Jun; 37 (6): 702-8
65. Choo MS, Song C, Kim JH, et al. Changes in overactive bladder neuromodusymptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol 2005; 174: 201-4
66. Kuipers ME, Krauwinkel WJ, Mulder H, et al. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs R D 2004; 5: 73-81
67. Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004; 44: 1023-33
68. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
69. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24
70. Brynne N, Stahl MM, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287-95
71. Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998; 63: 529-39
72. Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs 1998; 55: 813-22
73. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18: 277-304
74. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003; 4: 436-40
75. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004; 64: 2433-46
76. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-5
77. Roehrborn CG, van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257-61
78. Saad F, Nickel JC, Valiquette L, et al. Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. Can J Urol 2005; 12: 2745-54
79. Elhilali M, Emberton M, Matzkin H, et al. Long-term efficacy and safety of alfuzosin 10mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006; 97: 513-9
80. Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int 2005; 95 Suppl. 4: 12-8
81. Marberger M. Drug insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol 2006 Sep; 3 (9): 495-503
82. Johnson TM II, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003; 170: 145-8
83. Asplund R. Sleep disorders in the elderly. Drugs Aging 1999; 14: 91-103
84. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 2006 Feb; 21 Suppl. 1: S11-5
85. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: nature's most versatile biological signal? FEBS J 2006 Jul; 273 (13): 2813-38
86. Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 2004; 171: 1199-202
87. Meythaler JM, Clayton W, Davis LK, et al. Orally delivered hyperplabaclofen to control spastic hypertonia in acquired brain injury. J Head Trauma Rehabil 2004 Mar-Apr; 19 (2): 101-8
88. Taylor MC, Bates CP. A double-blind crossover trial of baclofen: a new treatment for the unstable bladder syndrome. Br J Urol 1979; 51: 504-5
89. Batra SC, Iosif CS. Female urethra: a target for estrogen action. J Urol 1983; 129: 418-20
90. Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 2002; 60 Suppl. 1: 64-71
91. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2003; (2): CD001405